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This year the Lasker DeBakey Clinical Research Award will be shared by Brian Druker, Nicholas 
Lydon, and Charles Sawyers for their development of a targeted molecular therapy for treating 
chronic myeloid leukemia. Their work demonstrated the ability of drugs directed against cancer-
causing oncogenes to turn a rapidly fatal malignancy into a manageable chronic disease.This year’s Lasker DeBakey Clinical 
Research Award is unique. Three scien-
tists, Brian Druker (Oregon Health and 
Science University), Nicholas Lydon (for-
merly of Novartis), and Charles Sawyers 
(Memorial Sloan-Kettering Cancer Cen-
ter), are being recognized for a study that 
failed to reach its designated endpoint 
(Druker et al., 2001). Cancer therapy has 
long been marked by toxic treatments 
including invasive surgery, damaging 
chemotherapy, and mutagenic radiation 
treatment. Despite numerous successes 
in controlling and even curing cancer 
using these nonspecific approaches, the 
side effects of these therapies have left 
both the public and many medical pro-
fessionals emotionally conflicted con-
cerning cancer treatment. As a result, 
the introduction of new cancer thera-
pies follows a highly scripted protocol. 
Before a drug can be tested for its ability 
to treat cancer, investigators must first 
determine its safety. Studies are usu-
ally carried out in cancer patients who 
have exhausted all other existing thera-
peutic options. In these Phase I clinical 
studies, such patients volunteer to take 
the unproven drug. Groups of patients 
take the drug in increasing doses until 
a dose-limiting side effect is observed. 
Only after a maximal safe dose and the 
potential toxicities of a drug are defined 
are investigators allowed to initiate stud-
ies to determine whether a drug will have 
therapeutic efficacy in the treatment of 
cancer.
The three scientists being honored 
with this year’s Lasker Clinical Award 
came together to test a new therapeu-
tic approach to cancer: the systemic 
administration of an inhibitor of the 
tyrosine kinase BCR-ABL, a mutant 
protein known to be involved in the pathogenesis of chronic myeloid leuke-
mia (CML). At the time they undertook 
their work, most scientists believed 
that tyrosine kinases were required for 
too many essential cellular functions 
and were too similar in structure to be 
safely inhibited in vivo. In 1999, Druker, 
Lydon, and Sawyers designed a Phase 
I dose-escalation trial of what was then 
known as STI-571, now known as ima-
tinib or Gleevec (Druker et al., 2001). 
Despite the study’s design and the pre-
vailing concerns, they failed to identify 
a maximally tolerated dose. Instead, at 
the termination of their study, 53 of 54 
of the CML patients treated with doses 
of 300 mg/day or more exhibited a com-
plete hematological response. These 
results were quickly confirmed in Phase 
II and Phase III clinical trials designed 
to prove therapeutic efficacy (Sawyers 
et al., 2002; O’Brien et al., 2003). The 
drug was approved for clinical use in 
2001. Today, close to 90% of the initial 
CML patients treated with imatinib have 
exhibited no disease progression and 
remain on treatment. The success of 
this study established for the first time 
that a somatically mutated gene that 
was causally involved in the pathogene-
sis of cancer could be safely and effec-
tively targeted for cancer treatment. As 
a result, hundreds of targeted molecular 
therapies are now in various stages of 
clinical development, and the ongoing 
analysis of the outcomes of these stud-
ies continues to provide new insight into 
cancer pathogenesis and progression.
Cancers Can Be Defined by Their 
Mutations
When viewed in isolation, the introduc-
tion of imatinib (Gleevec) is an important 
addition to medical therapy. However, Cell 138, Sewhen viewed as the reduction to practice 
of over 40 years of basic cancer research, 
it is an astonishing story (for review, see 
Druker, 2008). In the 1960s, CML was the 
first cancer shown to contain a recurring 
genetic alteration. Nowell and Hunger-
ford demonstrated that the cells isolated 
from CML patients contained an abnor-
mally small chromosome. In the 1970s, 
Janet Rowley and her colleagues dem-
onstrated that this “Philadelphia chro-
mosome” resulted from a chromosomal 
translocation between chromosomes 
9 and 22. In the 1980s, several groups 
were able to demonstrate that the fusion 
chromosome resulted in juxtaposition of 
the 3′ end of the cellular homolog of the 
v-Abl oncogene on chromosome 9 with 
the 5′ end of a gene encoded on chro-
mosome 22, given the name breakpoint 
cluster region (BCR). The protein product 
of this fusion was termed BCR-ABL.
Oncogenes Cause Cancer
At the time of the cloning and charac-
terization of the BCR-ABL fusion, char-
acterization of the retroviral ABL protein 
had demonstrated that it belonged to 
a subclass of oncogenic proteins that 
functioned as tyrosine kinases. Like 
other oncogenic tyrosine kinases, the 
ABL protein is an enzyme that adds 
phosphate groups to the tyrosines 
of substrate proteins. The BCR-ABL 
fusion protein created by the Phila-
delphia chromosome was also shown 
to have tyrosine kinase activity, and 
tyrosine modification of its substrates 
was shown to play a critical role in 
regulating protein-protein interactions 
to initiate signal transduction pathways 
that inform cell survival, growth, and 
proliferation. Introduction of BCR-ABL 
into the hematopoietic lineage of mice ptember 18, 2009 ©2009 Elsevier Inc. 1051
resulted in leukemia, implicating this 
oncogene in the pathogenesis of can-
cer. These studies provided a dramatic 
demonstration that chromosomal trans-
locations could lead to somatic altera-
tions in enzyme regulation that contrib-
ute to cancer pathogenesis.
Tyrosine Kinases and Cell Signaling
Work to characterize the biological 
functions of tyrosine kinases in the 
1980s implicated the normal homologs 
of the viral tyrosine kinases as compo-
nents of cell signaling that connected 
surface receptors to the regulation of 
gene transcription and expression. As 
each of these genes was characterized 
in greater detail, the emerging impor-
tance of tyrosine phosphorylation in 
regulating cell signaling led many basic 
biologists to conclude that these genes 
were unlikely cancer targets. However, 
this did not keep clinical oncologists 
from hypothesizing to their trainees 
that these genes might be therapeu-
tic targets if highly selective inhibitors 
could be developed. It is at this time 
that Brian Druker entered the field of 
medical oncology and became inter-
ested in the possibility of targeting 
tyrosine kinases as a cancer therapy. 
As an oncology fellow in Thomas Rob-
erts’ laboratory at the Dana Farber 
Cancer Institute, Druker was among 
the first to produce a monoclonal anti-
body against phosphotyrosine for use 
in studying the activity of tyrosine 
kinases in transformed cells. It was 
also during this time that Nicholas 
Lydon was given the task of leading a 
drug discovery program at Ciba-Geigy 
to screen their chemical libraries for 
compounds that could inhibit tyrosine 
kinases. At the time, most medicinal 
chemists believed that although broad 
kinase inhibitors might be found, they 
would never be specific enough to 
be used safely in vivo. As part of the 
program, Lydon and his colleagues 
began using the monoclonal antibody 
that Druker had made to study kinase 
activity and substrates (Buchdunger et 
al., 1996). Although a number of inhibi-
tors were produced as part of this pro-
gram, when screened against a panel 
of tyrosine kinases none were found 
to inhibit only a single tyrosine kinase 
(Zimmermann et al., 1997).1052 Cell 138, September 18, 2009 ©2009 Translating Basic Research
By 1993, Druker had set up his own 
laboratory at the University of Oregon 
and was trying to find a kinase inhibitor 
of BCR-ABL that might be developed 
for clinical use in the treatment of CML 
(Oda et al., 1994; Druker, 2008). For this 
effort, he contacted Lydon, who provided 
compounds his team had developed. 
Together they reported in 1996 that one 
of these substances had activity in kill-
ing cells transformed with BCR-ABL, but 
not cells transformed with the tyrosine 
kinase Src (Druker et al., 1996). In mice, 
the compound was found to be well tol-
erated, even though it inhibited several 
tyrosine kinases in addition to BCR-ABL. 
They were able to demonstrate in mice 
that the compound prevented the growth 
of BCR-ABL transformed cells. Based on 
this information, Druker began to estab-
lish a team to initiate clinical trials with the 
support of Novartis, which had acquired 
the compound as a result of the merger of 
Ciba-Geigy and Sandoz. Druker recruited 
Charles Sawyers from the University of 
California, Los Angeles and Moshe Tal-
paz from M.D. Anderson Cancer Center 
to join him. Together, the assembled team 
designed a pivotal Phase I clinical trial. In 
June of 1998 and May 2000, they enrolled 
80 patients in their dose-escalating Phase 
I trial (Druker et al., 2001). As noted above, 
though a dose-limiting toxicity was not 
defined, 98% of the patients treated with 
doses in excess of 300 mg/day showed a 
dramatic decline in their cancer cell bur-
den. A subsequent Phase III clinical trial 
(O’Brien et al., 2003)—the international 
randomized study comparing interferon 
and imatinib that was directed by Druk-
er—demonstrated the vast superiority 
of imatinib to prior therapies for chronic 
phase CML and determined that over 
95% of patients achieved a complete 
hematological response at the initiation 
of therapy. Further follow-up of this group 
was published in 2006 and demonstrated 
that 86% of the initial patients achieved a 
complete cytogenetic remission.
Not All CML Patients Benefit from 
Imatinib
CML is a relatively asymptomatic dis-
ease. Up to half of all patients are diag-
nosed as the consequence of routine 
blood testing incidental to their disease 
(Figure 1). The remaining patients are Elsevier Inc.diagnosed as a result of symptoms from 
the splenomegaly or anemia that occurs 
as a secondary consequence of the 
chronic myeloid proliferation. Untreated, 
most patients go on to a progressive form 
of the disease within 3 years, marked by 
the acquisition of additional cytogenetic 
abnormalities, a decline in mature blood 
cell numbers, and ultimately the appear-
ance of undifferentiated leukemic cells 
that mark the disease’s conversion to 
acute leukemia. Once a patient has con-
verted from chronic to acute leukemia, 
additional chemotherapeutic treatments 
have little efficacy. Despite initial prom-
ise, this continues to be true for imatinib 
and related tyrosine kinase inhibitors 
(Sawyers et al., 2002; Talpaz et al., 2006). 
When CML patients with progressive dis-
ease were treated, Druker and Sawyers 
observed that although many of these 
patients had an initial benefit from treat-
ment with imatinib, the result was rela-
tively short-lived (Sawyers et al., 2002). 
This prompted Sawyers to take the lead 
in characterizing this phenomenon. His 
laboratory characterized in detail an 
initial cohort of patients whose disease 
recurred despite continuous imatinib 
treatment (Gorre et al., 2001). In close to 
half of these patients, he found that drug 
resistance was associated with the out-
growth of cells that had mutations in the 
tyrosine kinase domain of BCR-ABL that 
locked the kinase in its active conforma-
tion and rendered it resistant to imatinib, 
which binds and locks the protein in its 
inactive state (Shah et al., 2002). This 
was the final brushstroke in this bench-
to-bedside masterpiece. The correla-
tion of these mutations to the relapse 
of patients being treated with imatinib 
provided an unequivocal proof that the 
efficacy of imatinib is related to its ability 
to specifically inhibit BCR-ABL.
These studies demonstrated once and 
for all that the inhibition of a carcinogenic 
lesion can safely and effectively prevent 
the inexorable progression that cancer 
exhibits in its untreated form. Together, 
these studies opened the molecular era 
of targeted therapy directed against 
oncogenic mutations. The combined 
contribution of the three awardees also 
provides an important example of the 
value of public-private cooperation. 
There is little doubt that the constant 
prodding of Druker and Sawyers led 
Novartis to support a Phase I trial of a 
drug that was felt to have limited com-
mercial potential. At the same time, the 
resources commanded by Lydon to 
engage in chemical discovery and lead 
drug modifications and characteriza-
tion cannot be duplicated in the current 
academic realm. Today, over 500 drugs 
based on the principles established by 
the discovery of imatinib are in clinical 
development. The oncology community 
has embraced the belief that targeted 
therapeutics hold the promise to provide 
more effective therapies for the treat-
ment of cancer, disassociated from the 
traditional side effects of chemotherapy.
Lessons Learned
Prior to the work of Druker, Lydon, and 
Sawyers, targeted molecular cancer ther-
apies did exist. However, these existing 
therapies were not directed at the onco-
genic mutations that led to cancer but 
instead to essential features required for 
both normal and neoplastic cells of cer-
tain lineages. This is best demonstrated 
by the role of hormonal manipulation for 
the treatment of breast and prostate can-
cer. Hormonal ablation led to regression 
of these tumors as well as the normal tis-
sue from which the tumor arose. As such, 
these therapies were associated with sig-
nificant toxicities, including the stimulation 
of menopausal symptoms in breast can-
cer patients and the complex physiologi-
cal and psychological effects of castra-
tion in patients with prostate cancer. Until 
the work of Druker, Lydon, and Sawyers, 
therapy directed against the root cause of 
a cancer had not been undertaken. Their 
combined work provided a therapy that is 
almost universally effective for a clearly 
defined subset of CML patients, namely 
patients in the chronic phase of the dis-
order with a demonstrable BCR-ABL 
translocation. Furthermore, their demon-
stration that therapeutic efficacy is tied to 
the presence of the BCR-ABL transloca-
tion reinforced the concept that surrogate 
markers could be used to identify subsets 
of cancer patients that are likely to benefit 
from a targeted therapeutic.
As successful as imatinib (Gleevec) 
has been in leading to a paradigmatic 
shift in the treatment of cancer, the work 
has also provided insights that challenge 
the notion of how widely or quickly its 
success will be replicated. Epidemio-Figure 1. Treating CML with Imatinib
Chronic myeloid leukemia (CML) is caused by a translocation in hematopoietic progenitor cells resulting 
in an oncogenic product called BCR-ABL that activates a signaling pathway required for cell proliferation 
and survival. The targeted molecular therapeutic imatinib (Gleevec) targets BCR-ABL and prevents its 
kinase activity. Successful treatment of CML with imatinib depends on the stage of the disease during 
which the drug is administered. Normal hematopoietic progenitor cells (yellow) have the ability to repli-
cate themselves and to produce progeny representing all of the lineages of the hematopoietic system. 
Hematopoietic progenitor cells expressing the BCR-ABL oncogene (green) self-replicate and produce 
mature blood cells at an enhanced rate. When these CML cells acquire additional mutations (+), they can 
transform into acute leukemia cells (gray) with an impaired ability to differentiate and an enhanced ability 
for self-renewal. These acute leukemic cells are resistant to imatinib as they are no longer dependent 
solely on BCR-ABL for growth and survival.logical and genetic analyses have shown 
that cancer occurs in a series of steps 
characterized by the acquisition of heri-
table somatic mutations. To date, tar-
geted treatments for cancer have proven 
most effective when tumors can be iden-
tified at an intermediate stage of trans-
formation. Gleevec is most effective 
as a single agent when it is introduced 
at a stage when the BCR-ABL trans-
location is essential for sustaining the 
growth and survival of the accumulating 
cancer cells. As the CML cells acquire 
additional somatic mutations that char-
acterize blast crisis and the conversion 
to acute leukemia (Figure 1), inhibition 
of BCR-ABL has little or limited impact 
for many patients, suggesting that these 
tumors are no longer solely dependent 
on BCR-ABL for their maintenance. A Cell 138, Separtial demonstration of this has been 
provided by the finding that broader 
spectrum tyrosine kinase inhibitors can 
display efficacy even in those patients 
who develop progressive disease with-
out carrying a BCR-ABL mutation that 
confers resistance to imatinib (Cortes et 
al., 2008). These observations will lead 
in ensuing years to combined targeted 
therapies, as reproducible and treatable 
secondary lesions are identified in this 
population.
These results suggest that, like the 
unique dependence of chronic phase 
CML on the BCR-ABL translocation 
product, we need to identify the com-
parable intermediate stages of disease 
in other malignancies. Already some 
examples come to mind. The role of Bcl-2 
translocations in follicular lymphoma ptember 18, 2009 ©2009 Elsevier Inc. 1053
may provide such an opportunity to treat 
these otherwise incurable malignancies 
before they progress to more aggressive 
forms of lymphoma. The role of isocitrate 
dehydrogenase 1 (IDH1) as an initiating 
genomic lesion in intermediate grade 
gliomas may provide an opportunity for 
treatment of these tumors before they 
progress to malignant glioblastomas. 
Whether similar stages for lung cancer or 
other common cancers exist remains to 
be determined. Imatinib itself has already 
led to a demonstration of the importance 
of identifying such intermediate stages 
of cancer development. One of the con-
cerns when imatinib was first introduced 
was that it was also known to inhibit two 
other tyrosine kinases, the PDGF recep-
tor and c-Kit. Following the initial work of 
Druker, Lydon, and Sawyers, the safety 
profile of imatinib prompted investiga-
tors to explore the use of this agent in 
the treatment of gastrointestinal stromal 
tumors, which exhibit activation of the Kit 
receptor as one of the initiating lesions. 
Imatinib treatment has provided signifi-
cant clinical benefit for a subpopulation of 
these patients (Demetri et al., 2002). The 
myeloproliferative disorder hypereosino-
philic syndrome has been demonstrated 
to correlate with a chromosomal translo-
cation involving the PDGF receptor (Cools 
et al., 2003). Treatment of patients with this 
translocation can promote hematological 
remission and prevent disease progres-
sion. As with CML, resistance to imatinib 
in this patient population has been corre-
lated with the acquisition of mutations in 
the PDGF receptor kinase domain.
Finally, recent studies reinforce the 
importance of treating patients with tar-
geted agents at the earliest possible 
presentation of their disease. The rate of 
relapse in patients with CML declines dra-
matically after the first 3 years of therapy, 
dropping to less than 1% per year by their 
5th year in therapy. Modeling experiments 
suggest that the higher rate of relapse 
seen in the first 3 years results from the 1054 Cell 138, September 18, 2009 ©2009 Eoutgrowth of clones bearing resistance 
mutations in the BCR-ABL gene already 
present at the start of therapy. Chronic 
treatment with imatinib appears to dra-
matically reduce the rate at which the per-
sistent cells carrying a BCR-ABL translo-
cation acquire additional mutations. This 
is in contrast to standard chemothera-
peutic agents. The majority of these are 
mutagenic and potentially accelerate 
the mutation rate of the cancer cells that 
are not eliminated by the therapy. Unfor-
tunately, for the patients it helps most, 
imatinib treatment must be maintained 
chronically. Even after years of therapy 
and complete absence of clinical disease, 
patients can continue to harbor BCR-ABL 
transformed cells. Patients who have dis-
continued imatinib have had their disease 
relapse. It appears from these clinical 
observations that there are sites in the 
bone marrow where CML progenitors can 
persist even when the survival benefits of 
BCR-ABL are suppressed. Alternatively, 
there may be sites of disease persistence 
where effective levels of imatinib are not 
obtained. However, as the years go by 
and second generation inhibitors also fail 
to completely eliminate the disease, this 
latter possibility seems less likely (Talpaz 
et al., 2006). The persistence of this res-
ervoir of cells is being studied in many 
laboratories. Understanding how and 
why such cells are retained will undoubt-
edly provide valuable insight into cancer 
pathogenesis. This year’s Lasker clinical 
prize awardees are being honored not 
only for bringing basic science discov-
eries from the bench to the bedside, but 
also for how their bedside research is 
stimulating a deeper and more funda-
mental understanding of cancer.
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